NCT00543101View on ClinicalTrials.gov

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
HIV Infections
Interventions
DRUG

Darunavir (DRV/r)

Switch to DRV/r at a dose of 600/100 BID for 48 weeks

DRUG

continue on current dual boosted PI

Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks

Trial Locations (5)

12208

Albany Medical Center, Albany

85012

Spectrum Medical Group, Phoenix

02319

AIDS Healthcare Foundation, Los Angeles

Unknown

Orlando Immunology Center, Orlando

02215

Community Research Initiative of New England, Boston

All Listed Sponsors
lead

Community Research Initiative of New England

OTHER

NCT00543101 - Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors | Biotech Hunter | Biotech Hunter